For research use only. Not for therapeutic Use.
Gavestinel (GV 150526) is a selective and potent the glycine site of the NMDA receptor antagonist. Gavestinel has neuroprotectant effects[1].
| Catalog Number | M100289 |
| CAS Number | 153436-22-7 |
| Synonyms | 3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylic acid |
| Molecular Formula | C18H12Cl2N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+ |
| InChIKey | WZBNEZWCNKUOSM-VOTSOKGWSA-N |
| SMILES | C1=CC=C(C=C1)NC(=O)C=CC2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O |
| Reference | [1]. J F Hoke, et al. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):867-72. |
